GLP-1s: Keep your patients informed If you’re looking for a patient-friendly way to explain...
Short Takes: November 21, 2025
Measuring your pharmacy. If you’re looking to grow or improve your pharmacy, you need to start with, well, knowing where you’re at. APC’s latest webinar, “Metrics that Motivate,” is all about how to create the right indicators — key performance indicators — so you’ve got real, actionable data points to set goals and measure performance. It’s available on demand now — check it out right here!
What Kentucky said… The Kentucky Board of Pharmacy released a “compounded compliance alert” for compounded GLP-1 medications — specifically, obtaining those drugs from 503B outsourcing facilities. Its alert really doesn’t feel like an alert to us. It’s just making clear what APC has always told our members: We know of no authority under which a 503B is allowed to prepare or distribute drugs containing semaglutide and tirzepatide. Thanks for agreeing with us!
Do your patients need a cellular recharge?. If some of your patients are getting older, they might be interested in this month’s article from the Partnership for Personalized Prescriptions: “NAD+: Recharging Energy at the Cellular Level.” It’ll give them a great overview of one of the more interesting and potentially useful supplements — one that decline with not just age, but due to stress, illness, or even poor sleep. Point ’em to it!
Pharma advertorials: unregulated and untamed. If you’re a pharmaceutical company that wants to get around those pesky laws regulating your advertising, what do you do? You hire people to make advertorials for you — social media “influencers” to influence their followers to buy your meds … without having to obey those rules about efficacy claims or listing side effects. Just don’t mention that you paid them, and you’re apparently in the clear, according to a new study out of the University of Chicago. The top drugs being hawked? GLP-1s (no surprise), ADHD stimulants, and autoimmune biologics.
Drugmaker DTC advertising. Even forgetting the social media shenanigans, pharma is spending big on direct-to-consumer ads. And why not? The US (and New Zealand) are the only places they’re allowed to, and — get this — they even get to use that spending as a tax write-off. Yep, taxpayers are effectively subsidizing drug ads, and AHIP goes into the details of their huge, and growing, consumer ad budgets.
Don’t forget our wholesaler survey. Should APC offer a compounding-focused “boutique” wholesaler as a benefit for our Pharmacy/Facility Members? One that offers items that are currently offered through the major retail wholesalers? If you’ve got an opinion, take a moment to let us know in our quick survey. Thank you!
